Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Shoulder Innovations Q2 2026 Earnings Call - Raised FY26 Revenue Guidance on 56% Growth and Accelerating Surgeon Adoption
Shoulder Innovations reported a second quarter that reads less like a typical orthopedic device cycle and more like a commercial engine firing on all cylinders. Revenue jumped 56 percent to $17.2 mill...
- Revenue surged 56% year-over-year to $17.2 million, driven by accelerating new surgeon onboarding and deeper utilization within the existing customer base.
- Full-year 2026 revenue guidance was raised to $67 million to $69 million, reflecting a 42% to 46% growth trajectory and signaling management’s high conviction in commercial execution.
- Gross margin expanded to 78.3%, supported by strong average selling prices and negotiated cost reductions, with management projecting sustained margin levels through year-end.
- +7 more takeaways
Blink Charging Co. Q2 2026 Earnings Call - Structural Margin Expansion and Cost Reset Target Q4 Breakeven
Blink Charging is shedding its growth-at-all-costs skin. The second quarter of 2026 reads less like a typical EV infrastructure update and more like a corporate restructuring in motion. Revenue guidan...
- Revenue guidance was cut to $83M-$90M after Blink walked away from unprofitable contracts and divested Envoy Technologies. Sequential revenue still rose 4.3% to $21.7M. Quality is replacing quantity.
- GAAP gross margin expanded 2,200 basis points to 38.9%. The jump came from shifting Level 2 production to contract manufacturers, optimizing hardware mix, and pricing owned charging sites more aggressively.
- Operating expenses fell 57% year-over-year to $14.7M. Compensation dropped 39% and G&A shrank to $1.8M. The restructuring is structural. Management will not reverse course.
- +7 more takeaways
Trevi Therapeutics Q2 2026 Earnings Call - $319 Million Cash Runway Extends Through 2030 as Sole Player Advances Chronic Cough Pipeline
Trevi Therapeutics closed the second quarter of 2026 with $319 million in cash and marketable securities, a balance sheet that comfortably funds its chronic cough development program through 2030. Man...
- Cash position stands at $319 million, extending operational runway through 2030 to fund IPF and non-IPF ILD development, the LAKE-2b RCC trial, and pre-commercial activities.
- OCEAN-1 phase III trial for IPF-related chronic cough launched in Q2, with OCEAN-2 phase III initiation targeted for Q3.
- LAKE-2b phase II-B trial for refractory chronic cough is enrolling across more than 200 global sites, with sample size re-estimation planned for Q4 at the 50% completion mark.
- +9 more takeaways
Westrock Coffee Company Q2 2026 Earnings Call - Free Cash Flow Turns Positive Ahead of Schedule as Capital Intensity Collapses
Westrock Coffee Company just crossed the finish line it spent years sprinting toward. The Q2 2026 print flips the script on a capital-intensive buildout that weighed on margins for years. Free cash fl...
- Consolidated adjusted EBITDA hit a record $21.3 million in Q2, up nearly 39% year-over-year.
- Free cash flow flipped positive in Q2, arriving a quarter ahead of the company’s original timeline.
- Consolidated net sales reached approximately $306 million, an 8.8% increase, with first-half sales up 24% to $614 million.
- +9 more takeaways
Senseonics Q2 2026 Earnings Call - Revenue and Margins Surge as In-House Commercialization Pays Off, Prompting Raised Full-Year Guidance
Senseonics delivered a quarter that validates its core strategic pivot. Full commercialization back in-house, combined with aggressive DTC marketing and the Eon Care insertion network, drove U.S. reve...
- Q2 net revenue reached $14.5 million, a 120 percent year-over-year increase driven by Eversense 365 adoption and the elimination of the Ascensia revenue share.
- U.S. revenue surged more than 150 percent to $12.6 million, with active prescribers growing 130 percent year over year.
- Gross margin expanded to 59 percent, beating prior guidance and marking the company’s strongest organic performance in history.
- +7 more takeaways
INmune Bio Q2 2026 Earnings Call - MHRA Alignment Clears Path for Late 2026 Ebstrocel Filing
INmune Bio is converging on a pivotal regulatory inflection point. Management confirmed formal MHRA alignment across clinical, non-clinical, and manufacturing packages for Ebstrocel, pushing the UK ma...
- MHRA alignment secured across CMC, non-clinical, and clinical packages, removing regulatory guesswork for the UK Ebstrocel filing.
- UK marketing authorization application targets late Q3 or early Q4 2026, with conditional approval sought for recessive dystrophic epidermolysis bullosa.
- Sequential global filings planned, including a European Medicines Agency submission in early 2027 and a US Biologics License Application in Q1 2027.
- +9 more takeaways
Natural Grocers Q3 FY2026 Earnings Call - Management Trims Full-Year Guidance as Basket Growth Offsets Transaction Declines
Natural Grocers delivered another quarter of measured resilience in a market that refuses to hand out free passes. Comparable store sales accelerated to 1.2%, but the math tells a clearer story. Shopp...
- Daily average comparable store sales accelerated to 1.2% from 0.5%, driven by a 3.1% increase in basket size that offset a 1.8% decline in transaction count.
- Npower Rewards program penetration rose two percentage points year-over-year to 84%, with members consistently outperforming non-members across sales, traffic, and basket size.
- Management lowered full-year fiscal 2026 comp sales guidance to 1.5-2.0% and diluted EPS guidance to $2.07-$2.11, reflecting a more cautious consumer environment.
- +7 more takeaways
Westwood Holdings Group Q2 2026 Earnings Call - Legacy Value Outflows Offset by Rapid ETF and Private Capital Scaling
Westwood Holdings Group reported steady second-quarter revenue of $25.3 million and economic earnings of $3.0 million, but the headline story is a structural pivot. The firm shed $1.6 billion in asset...
- Q2 revenue held at $25.3 million, up from $23.1 million a year ago, as ETF and private capital growth neutralized legacy AUM erosion.
- Net outflows reached $1.6 billion, concentrated in institutional large-cap value and small-cap strategies as clients rotate toward passive ETFs and consolidated mandates.
- The ETF platform crossed $400 million in July, with the Enhanced Income Series and YLDW fund gaining platform approvals despite recent net outflows.
- +8 more takeaways
SandRidge Energy Second Quarter 2026 Earnings Call - Zero-Debt Balance Sheet and Cherokee Expansion Fuel 49% EBITDA Growth
SandRidge Energy delivered another quarter of disciplined execution, turning higher oil averages near $95 per barrel into a 49 percent jump in adjusted EBITDA to $34 million. Management continues to t...
- Production and revenue surged, with output rising 11% year-over-year to 19.7 MBOE per day and revenue jumping 48% to roughly $51 million.
- Adjusted EBITDA expanded 49% to $34 million, driven by higher oil averages near $95 per barrel and strict cost controls.
- The balance sheet remains pristine with $115 million in cash, zero debt, and a negative net leverage position that insulates the company from market volatility.
- +7 more takeaways
Natuzzi S.p.A. Q1 2026 Earnings Call - Italian Plant Closures and Romania Production Shift Target Margin Recovery
Q1 2026 delivered a blunt wake-up call for Natuzzi. External headwinds like US tariffs, a frozen housing market, and geopolitical friction collided with an oversized Italian manufacturing base. Manage...
- Q1 2026 results were officially labeled disappointing, driven by US tariffs, historically low housing activity, weak consumer sentiment, and margin compression from relocating Natuzzi Editions production to Italy.
- Management is consolidating its Italian manufacturing footprint from five operating plants down to two to eliminate fixed costs that no longer match sales volume.
- Natuzzi Editions production for the US market will shift from Italy to Romania, a move designed to capture a 25 percent EBIT margin on roughly €30 million to €40 million in annual volume.
- +7 more takeaways